Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program
11. Mai 2021 08:00 ET
|
HalioDx
Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancerExpert clinical centers already involved worldwide in this new Innovation...
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil
10. Dezember 2020 07:45 ET
|
HalioDx
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil Marseille, France, December 10, 2020 HalioDx SAS, the immuno-oncology...
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients
03. Dezember 2020 07:45 ET
|
HalioDx
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological...
New data reinforces Immunoscore clinical utility in localized Colon Cancer
20. Oktober 2020 08:00 ET
|
HalioDx
New data reinforces Immunoscore clinical utility in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center
09. Oktober 2020 08:00 ET
|
HalioDx
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...
HalioDx contribution to precision medicine at ESMO 2020
18. September 2020 08:10 ET
|
HalioDx
HalioDx contribution to precision medicine at ESMO 2020 Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of...
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
10. September 2020 07:45 ET
|
HalioDx
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
Immunoscore included in ESMO Clinical Practice Guidelines 2020
06. August 2020 07:45 ET
|
HalioDx
Immunoscore® included in ESMO Clinical Practice Guidelines 2020 Marseille, France, August 06, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been...
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer
26. Mai 2020 07:45 ET
|
HalioDx
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of...
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19. Mai 2020 07:50 ET
|
HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies to characterize patients treated with ImCheck’s...